Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Mobocertinib · Exkivity, TAK-788

Small molecule · Inhibitor of epidermal growth factor receptor (EGFR) · developed by Takeda Pharms Usa

Approved FDA, Sep 2021
TAK Developer
2 Registered trials

What is Mobocertinib?

Mobocertinib is an orally available kinase inhibitor that irreversibly binds and inhibits EGFR exon 20 insertion mutations, with secondary activity against other EGFR family members HER2 and HER4. It is studied in non-small cell lung cancer, including advanced and metastatic disease with EGFR exon 20 insertion mutations.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Exkivity, TAK-788, AP-32788
Drug type
Small molecule
Targets
epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (ERBB2) (secondary target), human epidermal growth factor receptor 4 (ERBB4) (secondary target), BLK (secondary target)
Mechanism
Inhibitor of epidermal growth factor receptor (EGFR)
Pathways
EGFR signaling, tumor cell proliferation
Therapy area
Oncology
Developer
Takeda Pharms Usa (TAK)
FDA status
Approved as Exkivity (September 15, 2021), NDA215310 · FDA label
UNII
39HBQ4A67L

✅ FDA-approved uses

From the indications section of the FDA label (version of Feb 3, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04129502 Phase 3 Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Completed TAK
NCT03807778 Phase 1 Non-Small Cell Lung Cancer Active not recruiting TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-Small Cell Lung CancerAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Other drugs acting on EGFR

More from Takeda Pharms Usa

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind Mobocertinib

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.